This randomized noninferiority trial, named eSMARTER (Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results), evaluated whether a patient-centered digital platform is comparable to clinician-mediated telehealth for returning APOE genotype results and optional plasma pTau-217 results. The primary objective was to determine noninferiority of the digital approach versus clinician-mediated disclosure on short-term outcomes of AD-related knowledge, anxiety, and disease-specific distress.
The eSMARTER study was a fully decentralized, remote, randomized noninferiority trial conducted across the contiguous United States. Enrollment occurred between October 2024 and February 2025, with follow-up completed in November 2025. The trial randomized participants in a 2:1 ratio to the digital platform or clinician-mediated disclosure and included a 6-month post-APOE assessment before offering optional plasma pTau-217 disclosure via the same assigned modality.
Eligible participants were aged 60–80 years, had previously undergone APOE genotyping through the GeneMatch program without receiving results, passed psychological screening, had internet access, and were English-speaking. A total of 674 individuals met eligibility criteria and provided demographic information; 651 participants were randomized and completed APOE disclosure.
Baseline characteristics were reported as balanced between randomized groups. The cohort characteristics included a mean (SD) age of 68 (4.7) years, 451 (67%) female participants, and a mean (SD) telephone MoCA score of 19 (2).
Participants were randomized 2:1 to either the eSMARTER digital platform (n=435) or clinician-mediated telehealth disclosure (n=216). APOE genotype results were disclosed according to the assigned modality. Following the primary 6-month assessment, participants were offered optional disclosure of plasma pTau-217 via the same randomized modality.
Primary outcomes assessed at 1–7 days after APOE disclosure included changes in: (1) AD-related knowledge, (2) anxiety measured by PROMIS Anxiety, and (3) disease-specific distress. These outcomes were evaluated against a priori noninferiority margins. Secondary and longer-term outcomes included subsequent responses to optional plasma pTau-217 disclosure and study completion metrics.
Of the 651 participants who received APOE disclosure, genotype distribution was reported as: 66 (10%) APOE4 homozygotes, 377 (58%) heterozygotes, and 208 (32%) non-carriers. At 1–7 days post-disclosure, measures of AD-related knowledge, PROMIS Anxiety, and disease-specific distress in the digital disclosure group met the pre-specified noninferiority margins compared with the clinician-mediated disclosure group. No meaningful between-group differences were reported for these primary measures at that early time point.
Overall study completion included 604 participants. Baseline characteristics remained balanced across arms, supporting comparability between groups.
After the 6-month post-APOE assessment, 500 participants opted to receive plasma pTau-217 results through their randomized modality. The source reports that no significant between-group differences were found following pTau-217 disclosure. Specific numerical comparisons, effect sizes, or statistical values for pTau-217 disclosure outcomes were not detailed in the source beyond the statement of no significant between-group differences.
The trial protocol received approval from an Advarra institutional review board (IRB #Pro00064250), and all participants provided written informed consent. The trial is registered under Clinical Trial NCT06459583. The source states that deidentified study data are available on request by emailing APIData@bannerhealth.com; access requires a Data Use Agreement with Banner Health.
The study was supported by grants including National Institutes of Health awards (R01AG058468, P30AG072980) and institutional support. Multiple authors disclosed funding from the National Institute on Aging and other entities. Specific competing interests reported include institutional grants or contracts to Banner Health from industry, and personal or advisory relationships between some authors and companies involved in diagnostic assays, including contributors to plasma pTau-217 assay development. The source provides a detailed competing interest statement for individual authors.
The eSMARTER randomized noninferiority trial found that disclosure of APOE genotype via a patient-centered digital platform was non-inferior to clinician-mediated telehealth disclosure on short-term measures of AD-related knowledge, anxiety, and disease-specific distress. Optional plasma pTau-217 disclosure via the same modalities did not show significant differences between groups. The authors conclude that this digital platform may offer an evidence-based, scalable approach for returning genetic and biomarker results related to Alzheimer disease, while noting study oversight, registration, and data-sharing provisions as reported in the source.